1 option
Clinical review report : (Sun Pharma Global FZE) : Indication : for the Treatment of Adult Patients with Moderate-to-severe Plaque Psoriasis who are Candidates for Systemic Therapy Or Phototherapy. Tildrakizumab (Ilumya) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Series:
- Common drug review clinical review report.
- Common drug review clinical review report
- Language:
- English
- Subjects (All):
- Psoriasis--therapy.
- Psoriasis.
- Physical Description:
- 1 online resource (123 pages).
- Edition:
- Version: Final.
- Other Title:
- Clinical review report
- Place of Publication:
- Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- The objective of this report was to perform a systematic review of the beneficial and harmful effects of tildrakizumab 100 mg/mL for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Notes:
- Description based on online resource; title from PDF title page (Canadian Agency for Drugs and Technologies in Health, viewed April 22, 2023).
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.